Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 08/02/2019 (Notice of voluntarily dismissal)

Filing Date: March 12, 2019

According to the Complaint, Corbus Pharmaceutical Holdings, Inc. purports to be a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases.

The Complaint alleges that during the Class Period, and unbeknownst to investors, Corbus made false and/or misleading statements and/or failed to disclose that Corbus’ drug candidate, Lenabasum, had “failed its major trials in [systemic sclerosis] and [cystic fibrosis].”

On June 3, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel.

This case was voluntarily dismissed on August 2, 2019.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.